Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

1134153

USP

Cilostazol

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-chinolinon, OPC 13013, OPC 21, Pletaal

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C20H27N5O2
CAS-Nummer:
73963-72-1
Molekulargewicht:
369.46
MDL-Nummer:
MFCD00866780
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329749401
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

cilostazol

Hersteller/Markenname

USP

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

SMILES String

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChIKey

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Angaben zum Gen

human ... PDE3A(5139)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.

Anwendung

Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets

Hinweis zur Analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1134164

Cilostazol-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1134175

Cilostazol-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1134186

Cilostazol-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

PHR1503

Cilostazol, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1653

Cilostazol-verwandte Verbindung B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1676

Cilostazol-verwandte Verbindung C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2855

Cilostazol-verwandte Verbindung A, pharmaceutical secondary standard, certified reference material

Piktogramme

Health hazard
GHS08

Signalwort

Warning

H-Sätze

H361d

Gefahreneinstufungen

Repr. 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
Eun-Seok Shin et al.
Heart (British Cardiac Society), 100(19), 1531-1536 (2014-06-18)
We conducted a randomised, double blind, placebo controlled trial to assess the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase 3, in patients with vasospastic angina (VSA). Cilostazol has been shown to induce vascular dilatation, but its efficacy
Haeyeon Hong et al.
Clinical therapeutics, 36(8), 1290-1301 (2014-07-12)
Despite numerous efforts to develop effective medications for the treatment of intermittent claudication (IC) over the past 4 decades, a gold standard medical management option has yet to be defined. Although not life-threatening, IC interferes with mobility and activities of
Alexander J Ansara et al.
The Annals of pharmacotherapy, 46(3), 394-402 (2012-02-23)
To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke. PubMed and MEDLINE searches were performed (January 1970-September 2011) using the key words cilostazol, antiplatelet, aspirin, acetylsalicylic acid, secondary stroke prevention, ischemic stroke, intracerebral hemorrhage
Natnicha Kanlop et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 12(2), 88-95 (2011-01-05)
Cilostazol is a selective phosphodiesterase 3 (PDE3) inhibitor approved by the Food and Drug Administration for treatment of intermittent claudication. It has also been used in bradyarrhythmic patients to increase heart rates. Recently, cilostazol has been shown to prevent ventricular
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.